Bibliographic Details
| Title: |
Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study |
| Authors: |
Niko Kohmer, Shivana Stein, Barbara Schenk, Katharina Grikscheit, Melinda Metzler, Holger F. Rabenau, Marek Widera, Eva Herrmann, Sabine Wicker, Sandra Ciesek |
| Source: |
International Journal of Infectious Diseases, Vol 128, Iss , Pp 166-175 (2023) |
| Publisher Information: |
Elsevier, 2023. |
| Publication Year: |
2023 |
| Collection: |
LCC:Infectious and parasitic diseases |
| Subject Terms: |
Heterologous prime-boost, ChAdOx1-S, BNT162b2, Immunogenicity, Reactogenicity, Infectious and parasitic diseases, RC109-216 |
| More Details: |
Objectives: Regarding reactogenicity and immunogenicity, heterologous COVID-19 vaccination regimens are considered as an alternative to conventional immunization schemes. Methods: Individuals receiving either heterologous (ChAdOx1-S [AstraZeneca, Cambridge, UK]/BNT162b2 [Pfizer-BioNTech, Mainz, Germany]; n = 306) or homologous (messenger RNA [mRNA]-1273 [Moderna, Cambridge, Massachusetts, USA]; n = 139) vaccination were asked to participate when receiving their second dose. Reactogenicity was assessed after 1 month, immunogenicity after 1, 3, and/or 6 months, including a third dose, through SARS-CoV-2 antispike immunoglobulin G, surrogate virus neutralization test, and a plaque reduction neutralization test against the Delta (B.1.167.2) and Omicron (B.1.1.529; BA.1) variants of concern. Results: The overall reactogenicity was lower after heterologous vaccination. In both cohorts, SARS-CoV-2 antispike immunoglobulin G concentrations waned over time with the heterologous vaccination demonstrating higher neutralizing activity than homologous mRNA vaccination after 3 months to low neutralizing levels in the Delta plaque reduction neutralization test after 6 months. At this point, 3.2% of the heterologous and 11.4% of the homologous cohort yielded low neutralizing activity against Omicron. After a third dose of an mRNA vaccine, ≥99% of vaccinees demonstrated positive neutralizing activity against Delta. Depending on the vaccination scheme and against Omicron, 60% to 87.5% of vaccinees demonstrated positive neutralizing activity. Conclusion: ChAdOx1-S/BNT162b2 vaccination demonstrated an acceptable reactogenicity and immunogenicity profile. A third dose of an mRNA vaccine is necessary to maintain neutralizing activity against SARS-CoV-2. However, variants of concern-adapted versions of the vaccines would be desirable. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
1201-9712 |
| Relation: |
http://www.sciencedirect.com/science/article/pii/S1201971222006725; https://doaj.org/toc/1201-9712 |
| DOI: |
10.1016/j.ijid.2022.12.034 |
| Access URL: |
https://doaj.org/article/71587574b93e4fd791db7567f3c3fe3d |
| Accession Number: |
edsdoj.71587574b93e4fd791db7567f3c3fe3d |
| Database: |
Directory of Open Access Journals |
